Using CAR-T-cells for cancer treatment

MOL270: Anna-Maria Rasmussen Eitrheim, Ann-Mari Byrkjeland, Fredrik Eikevik & Helene Marie Vosskötter

Cultivate modified

t-cell

Figure 1: Illustration of

how CAR t-cells are made

from patiens own t-cells

Extract t-cells

from patient

Introduce

CAR t-cells back

into patient

CAR gene

Introduce CAR

gene to

reprogramme cell

What is it?

The immune system recognizes foreign substances in the body by detecting proteins on the surface of foreign cells. These proteins are known as **antigens**. CAR-T-cell immunotherapy is a new cancer therapy that uses the **body's own immune system** to fight the tumour. In CAR-T-cell therapy the patient's own immune cells (T-cells) are used, spliced with a Chimeric antigen receptor (CAR) gene.

genetically modified T-cells are returned to the patient's body where they seek out and destroy the tumor. Currently, this therapy is only used for certain types of cancer, such as lymphoma and leukemia and in Norway it is only available at University hospitals.

How does it work?

T-cells are extracted from the

patient's blood and genetically

engineered to recognize specific

antigens on cancer cells. The

Cancer T-cell surface protein Cancer surface protein CAR t-cell Chimeric antigen CAR t-cell Stigure 2: CAR t-cell attaching to cancer surface protein.

Side effects:

These usually occur within the first 14 days, while the patient is still in hospital and closely monitored. Most severe side effects include: •Cytokine release syndrome (CRS) • Neurotoxicity •Allergic reactions •Weakened immune system

Ethics:

Pros:

- Less severe side effects than chemotherapy.
 More effective and precise than chemotherapy.
 No immune response to
- your own immune cells.

- Cons:
- •Cost, 400 000 \$.
- Distribution of treatment.Potentially dangerous side effects.

DEPUTY

•Effective on only certain types of cancer.



and the second s

References:

CAR T-cell Therapy and Its Side Effects (no date). Available at: https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html (Accessed: 28 April 2025).

Nilsen, L.B. (2024) Banebrytende kreftbehandling blir snart landsdekkende tilbud. Available at: https://www.healthtalk.no/lymfom/car-t-blir-snart-landsdekkende-etparadigmeskifte/192048 (Accessed: 28 April 2025).

Sterner, R.C. and Sterner, R.M. (2021) 'CAR-T cell therapy: current limitations and potential strategies', Blood Cancer Journal, 11(4), pp. 1–11. Available at: https://doi.org/10.1038/s41408-021-00459-7.

